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Dihydrofolate reductase (DHFR) is a well-studied drug target and a paradigm for understanding
enzyme catalysis. Preparation of pure DHFR samples, in deﬁned ligand-bound states, is a prerequi-
site for in vitro studies and drug discovery efforts. We use NMR spectroscopy to monitor ligand con-
tent of human and Escherichia coli DHFR (ecDHFR), which bind different co-purifying ligands during
expression in bacteria. An alternate puriﬁcation strategy yields highly pure DHFR complexes, con-
taining only the desired ligands, in the quantities required for structural studies. Interestingly,
ecDHFR is bound to endogenous THF while human DHFR is bound to NADP. Consistent with these
ﬁndings, a designed ‘‘humanized’’ mutant of ecDHFR switches binding speciﬁcity in the cell.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Dihydrofolate reductase (DHFR) reduces dihydrofolate (DHF) to
tetrahydrofolate (THF), and is most often the sole source of THF in
cells. THF is a precursor for thymidine synthesis, and therefore for
DNA replication and cell proliferation. Due to its critical cellular
function, DHFR has been studied extensively for many years, as a
paradigm for understanding enzyme catalysis and as a target for
anticancer and antibiotic drugs [1–6]. Selection of the puriﬁcation
protocol is not always critical, but for certain experiments it is cru-
cial that the enzyme not be bound to undesired ligands. Previously
described methods for the expression and puriﬁcation of DHFR
from various sources, including Escherichia coli DHFR (ecDHFR)
and human DHFR (hDHFR) [7–10], rely on methotrexate (MTX)
afﬁnity or ion exchange chromatography to isolate the enzyme in
the native state, often bound to folate (FOL) or dihydrofolate
(DHF). Bound ligands are then removed by extensive dialysis or
isoelectric focusing [7]. For NMR experiments that focus on charac-
terizing differences between intermediates in the DHFR catalytic
cycle, it is imperative that the samples contain not even trace
amounts of contaminating ligands. After MTX afﬁnity puriﬁcation,
complete removal of ligands is not easily achieved for hDHFR; iso-
electric focusing is not efﬁcient at the scale required for structural
studies and is often not easily accessible.chemical Societies. Published by E
Martinez-Yamout), wright@Our detailed NMR studies of human and E. coli DHFR complexes
prompted us to evaluate the nature of ligands bound to DHFR pro-
duced via different puriﬁcation methods. Depending on the desired
enzyme complex and experimental plan, some puriﬁcation meth-
ods are more reliable than others, and can potentially impact the
results. Certain ecDHFR and hDHFR complexes can only be ob-
tained at a high level of purity by refolding apo-enzyme prepared
using reversed-phase HPLC puriﬁcation in the presence of the de-
sired ligand. Interestingly, our experiments also reveal the pre-
ferred ligands of both human and E. coli DHFR in E. coli cells;
while human DHFR is tightly bound to NADP+ or NADPH in the cell,
its E. coli counterpart is bound with high afﬁnity to THF. We found
this intriguing, given the high structural homology of the two en-
zymes, and pursued it further. We show that a humanized mutant
of ecDHFR, N23PP/S148A ecDHFR, is tightly bound to NADP instead
of THF. Since the conformation of ecDHFR is known to be ligand
dependent, our data yields useful information on the most preva-
lent conformational state in a cellular context, which may be of
use for drug design.
2. Materials and methods
hDHFR and ecDHFR were overexpressed and puriﬁed as de-
scribed in the Supplementary material and as previously reported
[8]. Two puriﬁcation strategies were used for hDHFR and ecDHFR:
a native puriﬁcation strategy using anion exchange followed by
size exclusion chromatography, and a novel reversed-phase HPLClsevier B.V. All rights reserved.
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hDHFR can be optimally achieved by rapid dilution, as the protein
does not refold efﬁciently at high concentrations. Brieﬂy, lyophi-
lized hDHFR and ecDHFR were solubilized in 8M urea, and refolded
by diluting dropwise into buffer without urea and with 10-fold ex-
cess ligand, with constant gentle stirring. hDHFR can be refolded
most efﬁciently at a ﬁnal protein concentration of 610 lM, while
ecDHFR can be refolded at a protein concentration of up to
100 lM. A detailed description of the refolding method is provided
in the Supplementary material. Kinetic measurements were made
as described in the Supplementary material and Fig. S1. Standard
1H–15N HSQCs were recorded at 750 MHz or 600 MHz, at a temper-
ature of 300 K.
3. Results and discussion
3.1. Human DHFR is optimally stable when expressed in the presence
of folic acid
Our expression protocol for hDHFR differs from previously pub-
lished methods in one signiﬁcant aspect: the cells are grown in the
presence of 2 mM folic acid (folate). Comparison of the 15N-HSQC
spectra of hDHFR in cell lysates derived from cells grown in med-
ium with and without added folate clearly indicates that hDHFR
expressed in the presence of folate is well folded and stable, with
well dispersed peaks in the proton dimension, whereas hDHFR ex-
pressed in the absence of folate is largely aggregated or misfoldedFig. 1. hDHFR is optimally folded and stable when expressed in the presence of folic acid
hDHFR lysate, expressed with 2 mM folic acid.
Fig. 2. 1H–15N HSQC spectra for ternary complexes of E. coli DHFR show that ecDHFR ca
HPLC puriﬁed protein (red) are shown for: ecDHFR:NADP:FOL (A) and ecDHFR:NADPH:T(Fig. 1). Subsequent addition of either folic acid or NADP+ to hDHFR
expressed without folate does not result in any change of the spec-
trum shown in Fig. 1a, indicating that once the protein is misfolded
and/or aggregated, it cannot be recovered. This result shows that
under our experimental conditions, hDHFR overexpressed in
E. coli folds optimally and is stable only when the medium is sup-
plemented with excess folate, yielding higher recovery of hDHFR
per liter of labeled medium than previously reported [7].
3.2. Natively puriﬁed and refolded ecDHFR have identical 1H–15N
HSQC spectra and activity
Prior to employing the reversed-phase HPLC and refolding
method to human DHFR, we tested this method on ecDHFR, as
ecDHFR is more robust than hDHFR. Complexes of ecDHFR (puri-
ﬁed under native conditions as previously reported [8]) corre-
sponding to all stable intermediates in the catalytic cycle were
prepared and 1H–15N HSQC spectra were recorded. For ecDHFR:-
NADP+:FOL, ecDHFR:NADP+:THF, ecDHFR:NADPH:THF and
ecDHFR:THF, the 1H–15N HSQC spectra are identical for samples
made using either puriﬁcation method, showing that the re-
versed-phase puriﬁcation method followed by refolding works
well (Fig. 2), and also indicating that either method can be used
to reliably prepare these complexes. In addition, we measured
the activity of ecDHFR prepared under native and refolded condi-
tions, and show that the enzyme activity is unchanged by refolding
in vitro (Fig. S1).. (A) 1H–15N HSQC of hDHFR lysate, expressed without folic acid. (B) 1H–15N HSQC of
n be refolded successfully. Spectra of natively puriﬁed protein (black) and refolded
HF (B).
Fig. 3. NADP co-puriﬁes with hDHFR under native puriﬁcation conditions. (A)
1H–15N HSQCs of hDHFR puriﬁed using anion exchange followed by gel ﬁltration,
with addition of excess folic acid (black) and NADP+, and with addition of excess
NADP+ and folic acid (red). (B) 1H–15N HSQC spectra of hDHFR puriﬁed under native
conditions with addition of excess folic acid (black) and hDHFR puriﬁed by
reversed-phase HPLC and refolded with addition of excess NADP+ and folic acid
(magenta) are almost identical, showing that hDHFR can be successfully refolded.
(C) 1H–15N HSQC spectra of hDHFR:NADP+:FOL (red) and hDHFR:FOL (blue)
prepared by refolding HPLC puriﬁed apo-hDHFR with the respective ligands.
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with endogenously bound NADP
The purity of hDHFR resulting from our native puriﬁcation
strategy involving anion exchange and gel ﬁltration chromatogra-
phy is suitable for NMR spectroscopy, and the sample produces
excellent 1H–15N HSQC spectra (Fig. 3a). However, this protocol
yields protein that is bound to NADP, despite the fact that exoge-
nous NADP was not added at any step during expression or puriﬁ-
cation. hDHFR binds a mixture of endogenous NADP+ and NADPH
in the cell. Bound NADPH will be converted to NADP+ in the pres-
ence of folic acid; therefore our samples are contaminated with
NADP+. However, due to the ambiguity of the endogenously bound
ratio of NADP/NADPH, we refer to the bound cofactor simply as
NADP. Spectra of natively puriﬁed hDHFR show that addition of ex-
cess NADP+ to the ‘‘hDHFR:FOL’’ complex does not result in the
large chemical shift changes expected upon formation of the ter-
nary hDHFR:NADP+:FOL complex. Amide chemical shifts are highly
sensitive to chemical environment; therefore, addition of a ligand
should result in large chemical shift changes, especially in the li-
gand-binding site.
Given this perplexing result, we hypothesized that hDHFR pre-
pared by our native puriﬁcation strategy contains endogenously
bound NADP, and thus further addition of NADP+ does not result
in any chemical shift changes in the 1H–15N HSQC spectrum. This
was conﬁrmed by isolation of apo-hDHFR using our novel re-
versed-phase HPLC puriﬁcation strategy. HPLC puriﬁed apo-hDHFR
refolded in the presence of NADP+ and folic acid has an identical
1H–15N HSQC spectrum to that of natively puriﬁed hDHFR bound
to endogenous NADP and excess folate (Fig. 3b).
Under our native puriﬁcation conditions, extensive dialysis is
not sufﬁcient to remove the ligands from the ternary complex
(data not shown). This puriﬁcation method is only suitable for
obtaining the hDHFR:NADP+:FOL complex. Using samples prepared
with apo-hDHFR puriﬁed by reversed-phase HPLC, it is possible to
compare the spectra of the binary hDHFR:FOL and ternary
hDHFR:NADP+:FOL complexes (Fig. 3c). As for ecDHFR, the spectra
of the natively puriﬁed and refolded ternary complexes are identi-
cal (Fig. 2b) and the activity of the enzyme is maintained (Fig. S1).
The spectrum of the binary hDHFR:FOL complex is well dispersed
and of uniform intensity. Several crosspeaks exhibit large chemical
shift changes between the true hDHFR:FOL complex and the
hDHFR:NADP+:FOL ternary complex. As expected, these resonances
correspond to residues in the NADP binding site.
3.4. Puriﬁcation of E. coli DHFR under certain native conditions shows
the presence of endogenously bound THF
Analysis of several spectra revealed that ecDHFR samples pre-
pared from protein puriﬁed using the ion exchange-size exclusion
native puriﬁcation strategy were contaminated with THF (Fig. 4).
As no THF is added at any step of the procedure, we conclude that
THF endogenous to the E. coli cells binds the enzyme during over-
expression, and remains bound throughout the puriﬁcation. Based
on the intensity of minor peaks in the natively puriﬁed ecDHFR:-
NADPH spectra, which correspond directly to the ecDHFR:-
NADPH:THF resonances, we conclude that 5–7% of puriﬁed
ecDHFR contains bound THF.
The percentage of bound THF is dependent on, amongst other
things, the protein yield and total induction time. The residual
THF cannot be removed easily, even by extensive dialysis. Puriﬁca-
tion of WT ecDHFR using MTX afﬁnity chromatography will not re-
sult in this contamination since ecDHFR bound to THF cannot bind
the MTX afﬁnity column. We therefore conclude that for studies on
E. coli DHFR complexes without THF, puriﬁcation by reversed-
phase HPLC or traditional MTX afﬁnity puriﬁcation [9] is preferred.3.5. Designed ecDHFR mutant switches binding speciﬁcity in the cell
Natively puriﬁed hDHFR contains endogenously bound NADP,
while natively puriﬁed ecDHFR (by the ion exchange-size exclusion
method) contains endogenously bound THF. We evaluated the
endogenous ligand binding propensities of an ecDHFR mutant
(N23PP/S148A ecDHFR), in which the active site loops of the
E. coli enzyme were ‘‘humanized’’ by substitution of residues from
the human sequence to lock the enzyme in a closed conformation
[11]. The 1H–15N HSQC of natively puriﬁed N23PP/S148A ecDHFR
expressed without exogenous ligands added to the medium
Fig. 5. N23PP/S148A ecDHFR is bound to endogenous NADP after native puriﬁcation by ion exchange and size exclusion chromatography. (A) 1H–15N HSQC of natively
puriﬁed N23PP/S148A ecDHFR without addition of any ligand (black), showing several more resonances than residues in the protein. Upon addition of NADPH to this sample,
the E:NADPH complex is formed (red), in which a clean spectrum of uniform intensity is obtained, with one resonance per residue. The E:NADPH spectrum overlays almost
perfectly with a subset of the peaks in the black spectrum, showing that NADP is present in50% of the natively puriﬁed protein sample without any exogenous ligand added.
(B) 1H–15N HSQC of natively puriﬁed mutant protein with added folate (black) exhibits more resonances than expected for a uniform E:FOL complex. Overlay of this spectrum
with E:NADP+:FOL (red) shows that endogenously bound NADP is present in the natively puriﬁed sample.
Fig. 4. ecDHFR:NADPH binary complex is contaminated with bound THF. (A) 1H–15N HSQC of ecDHFR puriﬁed using anion exchange and gel ﬁltration, with addition of excess
NADPH. Several minor peaks are visible, indicating the presence of another species. (B) Overlay of A (black) with ecDHFR:NADPH prepared by HPLC puriﬁcation (red) and
ecDHFR:NADP+:THF (cyan). The sample prepared using HPLC puriﬁcation (red) does not contain the minor peaks observed in A. The minor peaks can be accounted for by the
ecDHFR:NADP+:THF (cyan) spectrum. The minor peaks arise from contamination with endogenous THF, which remains bound to ecDHFR throughout the anion exchange and
gel ﬁltration puriﬁcation steps.
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gand bound species that likely correspond to the apo enzyme
and E:NADP. Addition of excess NADPH to this sample resolves
the heterogeneity and yields a single set of peaks corresponding
to the E:NADPH complex (Fig. 5a). Addition of folate to the natively
puriﬁed sample shown in Fig. 5a results in a 1H–15N HSQC with
two sets of peaks, likely corresponding to E:FOL and E:NADP+:FOL
complexes (5b). Unlike wild type ecDHFR, the 1H–15N HSQC of
N23PP/S148A with added NADPH shows only a single set of reso-
nances with uniform intensity, conﬁrming that endogenous THF
is not present and that the ‘‘humanized’’ E. coli mutant shows a
similar speciﬁcity for endogenous ligands as hDHFR.
4. Conclusions
Our work addresses two issues that are relevant to further stud-
ies on DHFR. First, our data reveal the presence and identity of
endogenously bound ligands to hDHFR and ecDHFR expressed in
E. coli. Second, since the presence of these endogenously bound li-
gands might not be desirable for certain experiments, we present
suitable puriﬁcation strategies for obtaining pure samples of hu-
man and E. coli DHFR.
For the purpose of detailed NMR and other structural studies, it
is important to generate samples that contain only the desiredligands. Our data show that for wild type hDHFR, any native puri-
ﬁcation strategy will likely result in contamination with NADP.
When hDHFR is expressed in the presence of folic acid, which
boosts the yield of properly folded protein, a ternary complex
(hDHFR:NADP+:FOL) is formed. ecDHFR, on the other hand, is con-
taminated with THF after anion exchange and size exclusion chro-
matography. Neither contaminant can be removed by extensive
dialysis following native puriﬁcation.
While, in general, native puriﬁcation strategies are preferred in
order to maintain native structure and enzyme activity, we have
shown that in the case of human and E. coli DHFR, highly pure,
homogeneous and active enzyme complexes are optimally pre-
pared by refolding reversed-phase HPLC puriﬁed apo-enzyme in
the presence of the desired ligands. A partial refolding strategy
has been described [12] for preparation of folate-free ecDHFR,
but this method has yet to be applied to enzymes with less robust
refolding properties, such as hDHFR for which refolding under less
than optimal conditions results in considerably reduced yields
[13,14]. For both DHFRs, puriﬁcation by reversed-phase HPLC
yields protein that is ligand-free, and that can efﬁciently be re-
folded into the desired complex at the scales required for structural
studies and drug development. hDHFR NMR samples have previ-
ously been prepared by expression of hDHFR in the presence of tri-
methoprim, followed by methotrexate afﬁnity puriﬁcation, and
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bound ligands [15]. Binary hDHFR:MTX complexes prepared in this
manner did not contain observable bound NADP. However, this
work (15) used a different cell line, with likely different endoge-
nous ligand concentrations, for protein expression. Additionally,
the protein was stabilized using trimethorpim (TMP) in the med-
ium instead of folate. The afﬁnity of NADP is higher for hE:FOL than
for apo hE [5], and the afﬁnity of FOL for hE is higher than that of
TMP for hE [16]. It follows that since the afﬁnity of NADP for hE:-
FOL is higher than for hE:TMP, NADP likely binds with higher afﬁn-
ity when the enzyme is expressed in the presence of FOL than in
the presence of TMP, and thus copuriﬁes when the enzyme is ex-
pressed in the presence of FOL. It is therefore important to note
that depending on the afﬁnity and cooperativity of binding, and
the ligand used for stabilization during expression, different li-
gands might copurify with the enzyme.
The presence of endogenously bound ligands after native DHFR
puriﬁcation has been considered in the past during preparation of
DHFR. However, the identity of the bound ligands remained un-
known. Our results show that while ecDHFR is preferentially
bound to THF, and does not co-purify with endogenous NADP,
hDHFR co-puriﬁes with endogenous NADP. Moreover, a mutant
of ecDHFR designed to mimic the human sequence switches bind-
ing afﬁnities to resemble the human enzyme, and correspondingly,
is puriﬁed bound to endogenous NADP and not THF. The differen-
tial ligand-binding properties of ecDHFR, hDHFR and mutant
ecDHFR are consistent with reported dissociation constants;
hDHFR binds NADP with higher afﬁnity than ecDHFR does (for
hDHFR, Kd = 2.3 lM for NADP+, Kd = 0.05 lM for NADPH, while for
ecDHFR Kd = 24 lM for NADP+, Kd = 0.33 lM for NADPH)
[3,5,17,18]. The dissociation constants for these ligands are in the
high nanomolar-low micromolar range, and are for the apo en-
zymes. As has been shown before, there is some cooperativity in li-
gand binding [5]; therefore, it is likely that the afﬁnities of these
ligands are somewhat higher in the cell lysate. It is interesting to
note that a large number of structures deposited in the PDB contain
unexpected copurifying ligands, including 65% of the structures
solved by the Protein Structure Initiative (PSI) [19]. These ligands
can be acquired at the expression stage (as in the case of DHFR),
or at any of the puriﬁcation or crystallization stages, as buffer com-
ponents can often mimic ligands. As seen in the case of DHFR, the
co-purifying ligands need not bind with particularly high afﬁnity,
and the dissociation constants can be in the low micromolar range.
Since several proteins, including ecDHFR, exhibit ligand-dependent
conformational changes, an understanding of endogenously bound
ligands may yield insights into protein conformations in the cellu-
lar environment.
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